Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective
Author(s)
Navin Bithal, BSc1, Tariq Rehman, BSc, MBA1, Michael Frank Mørup, MSc2, Richard Bruggraber, BSc1, fallon Obam, MSc3.
1UCB, Berkshire, United Kingdom, 2UCB, Copenhagen, Denmark, 3Apogee Access, London, United Kingdom.
1UCB, Berkshire, United Kingdom, 2UCB, Copenhagen, Denmark, 3Apogee Access, London, United Kingdom.
OBJECTIVES: This study aimed to compare the cost per responder (CPR) of bimekizumab a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, against other approved IL-17A, IL-12/23, and IL-23 inhibitors for the treatment of psoriatic arthritis (PsA) in the UK over a 52-week timeframe.
METHODS: A 52-week CPR model was developed, incorporating both induction and maintenance treatment period. The model incorporated clinical efficacy based on American College of Rheumatology (ACR50) and Minimal Disease Activity (MDA) endpoints in PsA patients. In the absence of head-to-head trials, unanchored matching adjusted indirect comparisons (MAICs) were used to estimate long-term comparative efficacy between bimekizumab and other licensed IL inhibitors. Treatment costs were derived using NHS list prices (BNF 2025) and standard dosing regimens over 52 weeks. For each pairwise comparison (PwC), the CPR was calculated by dividing the cost per patient over 52 weeks by the corresponding clinical response rates. Treatments included bimekizumab (BKZ), secukinumab (SEC), ixekizumab (IXE), guselkumab (GUS), ustekinumab (UST), and risankizumab (RIS).
RESULTS: Bimekizumab demonstrated the lowest cost per response across all IL inhibitors in both biologic-naïve and biologic-experienced PsA populations. For ACR50 response: BKZ/GUS PwC achieved the most favourable CPR result in biologic-naïve (£30,348) and biologic-experienced (£34,161) populations; RIS had the highest CPR in both populations (£46,121 and £91,966 respectively). For MDA response: Among biologic-naïve patients, BKZ/SEC PwC showed the most favourable CPR at £33,870, while GUS had the highest at £58,065; among biologic-experienced patients, BKZ/GUS PwC again achieved the lowest CPR at £40,775 per responder, whereas SEC had the highest CPR at £91,966.
CONCLUSIONS: Bimekizumab consistently demonstrated the lowest cost per response for both ACR50 and MDA outcomes across IL inhibitors in biologic-naïve and biologic-experienced PsA populations over a 52-week period, supporting its potential as a cost-effective treatment option in UK clinical practice.
METHODS: A 52-week CPR model was developed, incorporating both induction and maintenance treatment period. The model incorporated clinical efficacy based on American College of Rheumatology (ACR50) and Minimal Disease Activity (MDA) endpoints in PsA patients. In the absence of head-to-head trials, unanchored matching adjusted indirect comparisons (MAICs) were used to estimate long-term comparative efficacy between bimekizumab and other licensed IL inhibitors. Treatment costs were derived using NHS list prices (BNF 2025) and standard dosing regimens over 52 weeks. For each pairwise comparison (PwC), the CPR was calculated by dividing the cost per patient over 52 weeks by the corresponding clinical response rates. Treatments included bimekizumab (BKZ), secukinumab (SEC), ixekizumab (IXE), guselkumab (GUS), ustekinumab (UST), and risankizumab (RIS).
RESULTS: Bimekizumab demonstrated the lowest cost per response across all IL inhibitors in both biologic-naïve and biologic-experienced PsA populations. For ACR50 response: BKZ/GUS PwC achieved the most favourable CPR result in biologic-naïve (£30,348) and biologic-experienced (£34,161) populations; RIS had the highest CPR in both populations (£46,121 and £91,966 respectively). For MDA response: Among biologic-naïve patients, BKZ/SEC PwC showed the most favourable CPR at £33,870, while GUS had the highest at £58,065; among biologic-experienced patients, BKZ/GUS PwC again achieved the lowest CPR at £40,775 per responder, whereas SEC had the highest CPR at £91,966.
CONCLUSIONS: Bimekizumab consistently demonstrated the lowest cost per response for both ACR50 and MDA outcomes across IL inhibitors in biologic-naïve and biologic-experienced PsA populations over a 52-week period, supporting its potential as a cost-effective treatment option in UK clinical practice.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE74
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)